Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
0(0%)
Results Posted
25%(2 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_4
1
8%
Ph phase_2
6
50%
Ph phase_1
3
25%
Ph phase_3
1
8%

Phase Distribution

3

Early Stage

6

Mid Stage

2

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
3(27.3%)
Phase 2Efficacy & side effects
6(54.5%)
Phase 3Large-scale testing
1(9.1%)
Phase 4Post-market surveillance
1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(8)
Terminated(2)
Other(2)

Detailed Status

Completed8
Terminated2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (27.3%)
Phase 26 (54.5%)
Phase 31 (9.1%)
Phase 41 (9.1%)

Trials by Status

completed867%
terminated217%
unknown217%

Recent Activity

0 active trials
Showing 5 of 12
terminatedphase_2

CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

NCT03387592
completedphase_1

A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.

NCT01916447
completed

An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors

NCT01040312
completedphase_2

Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer

NCT00201747
unknownphase_3

A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

NCT03303495
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT03387592Phase 2

CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

Terminated
NCT01916447Phase 1

A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.

Completed
NCT01040312

An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors

Completed
NCT00201747Phase 2

Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer

Completed
NCT03303495Phase 3

A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

Unknown
NCT02401971Phase 4

Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer

Unknown
NCT00003950Phase 2

Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer

Completed
NCT00476827Phase 2

A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain

Terminated
NCT00280787Phase 2

Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim

Completed
NCT00346801Phase 1

CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)

Completed
NCT00251407Phase 1

Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies

Completed
NCT00412542Phase 2

Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12